Scribe Therapeutics is adding another $100 million to its coffers six months after unveiling a $20 million series A and a partnership with Biogen to work on gene editing treatments for amyotrophic lateral sclerosis (ALS). The new funds will support the development of the company’s gene editing and delivery technologies and propel a pipeline of treatments for neurodegeneration and other diseases.

Entrada Therapeutics has raised $116 million to develop intracellular biologics. The series B round will enable Entrada to start clinical development of a pipeline featuring treatments for diseases such as Duchenne muscular dystrophy (DMD).

Flagship Pioneering has named Michael Nally as CEO-partner. The venture capital shop has put the former Merck executive in charge of machine-learning-enabled drug discovery play Generate Biomedicines.

Tyra Biosciences raised $50 million in early 2020 to get the ball rolling on a pipeline against drug-resistant cancers. Now, the company is gearing up to see its first program into clinical trials, and it’s banking $106 million and expanding its leadership team to get there.

It’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded pipeline.

Omega Therapeutics is taking it up a notch. The “genome-tuning” biotech raised $126 million to get its lead program, a treatment for liver cancer, into the clinic as well as to advance a clutch of other preclinical prospects including a treatment for acute respiratory distress syndrome (ARDS), a life-threatening lung injury that can result from COVID-19 infection.

Shortly after unveiling plans to spin its multibillion-dollar women’s health portfolio into the new company Organon, Merck & Co. has already lined up what will be its first acquisition: Alydia Health, which makes a device designed to prevent a mother’s death during childbirth.

Just over a year after Wave Life Sciences cut staffers, threw out a Duchenne muscular dystrophy med and saw its Huntington’s disease drug flop in a key test, the waves come crashing down again for the biotech.

For years, innovations in the treatment of pulmonary valve regurgitation have relied on invasive surgical treatments—until now. A device from Medtronic that takes a minimally invasive approach to treating patients with congenital heart disease has become the first of its kind to snag approval from the FDA.

Clinical stage immuno-oncology innovator GT Biopharma, Inc. (NASDAQ: GTBP) is targeting multiple hematologic and solid tumor cancers with its first-in-class NK cell engager protein biologic technology platform: TriKE™.  TriKE™ is designed to rescue the patient’s native natural killer cell (NK cell) population.  Additionally, TriKE™ has the unique ability to be a self-sustaining,
self-activating, target-directed NK cell therapeutic agent – resulting in a persistent, 24/7 serial cancer cell killer, lasting for 60-90 days – without the need to transplant NK cells in patients or be co-administered with other therapeutic agents.  For these reasons, GT Biopharma’s novel TriKE™ therapy will be significantly less expensive than other cancer treatments, opening the door to an off-the-shelf therapeutic for patients.

GT Biopharma recently reported updated interim Phase I/II clinical trial results for its lead therapeutic candidate, GTB-3550 TriKE™. GTB-3550 is currently being evaluated for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML).  Highlights of the results include: